<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    15056503
   </pmid>
   <datecreated>
    <year>
     2004
    </year>
    <month>
     04
    </month>
    <day>
     01
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2004
    </year>
    <month>
     06
    </month>
    <day>
     24
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2004
    </year>
    <month>
     11
    </month>
    <day>
     17
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0002-953X
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       161
      </volume>
      <issue>
       4
      </issue>
      <pubdate>
       <year>
        2004
       </year>
       <month>
        Apr
       </month>
      </pubdate>
     </journalissue>
     <title>
      The American journal of psychiatry
     </title>
     <isoabbreviation>
      Am J Psychiatry
     </isoabbreviation>
    </journal>
    <articletitle>
     Management of bipolar disorder during pregnancy and the postpartum period.
    </articletitle>
    <pagination>
     <medlinepgn>
      608-20
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      Bipolar disorder affects 0.5%-1.5% of individuals in the United States. The typical age at onset is late adolescence or early adulthood, placing women at risk for episodes throughout their reproductive years. General guidelines for the treatment of bipolar disorder are available from the American Psychiatric Association, but additional issues arise when these guidelines are applied in the treatment of peripartum women. The authors summarize knowledge regarding the management of bipolar disorder during pregnancy and the postpartum period, with a focus on managing mania, hypomania, and the psychotic components of the illness.
     </abstracttext>
     <abstracttext label="METHOD" nlmcategory="METHODS">
      An expert panel reviewed articles that address the management of bipolar disorder and the consequences of the use of mood stabilizers during pregnancy, and a consensus document was generated.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      The treatment of bipolar disorder in pregnant women involves significant challenges. Some mood stabilizers, e.g., sodium valproate and carbamazepine, are human teratogens. On the other hand, the teratogenicity associated with lithium may have been overestimated in the past.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Since treatment can be managed most effectively if pregnancy is planned, clinicians should discuss the issue of pregnancy and its management with every bipolar disorder patient who has childbearing potential, regardless of future reproductive plans. Additional research should address the risks of disturbed sleep to pregnant and postpartum women with bipolar disorder, as well as structural and behavioral consequences to offspring when mood stabilizers are used during pregnancy. Longitudinal and cohort studies can promote these efforts. Given the rate of bipolar disorder in the general population, research efforts will need to be broad based and include multiple collaborating centers.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA. kimberly.yonkers@yale.edu
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Yonkers
      </lastname>
      <forename>
       Kimberly A
      </forename>
      <initials>
       KA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wisner
      </lastname>
      <forename>
       Katherine L
      </forename>
      <initials>
       KL
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Stowe
      </lastname>
      <forename>
       Zachary
      </forename>
      <initials>
       Z
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Leibenluft
      </lastname>
      <forename>
       Ellen
      </forename>
      <initials>
       E
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Cohen
      </lastname>
      <forename>
       Lee
      </forename>
      <initials>
       L
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Miller
      </lastname>
      <forename>
       Laura
      </forename>
      <initials>
       L
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Manber
      </lastname>
      <forename>
       Rachel
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Viguera
      </lastname>
      <forename>
       Adele
      </forename>
      <initials>
       A
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Suppes
      </lastname>
      <forename>
       Trisha
      </forename>
      <initials>
       T
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Altshuler
      </lastname>
      <forename>
       Lori
      </forename>
      <initials>
       L
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Review
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Am J Psychiatry
    </medlineta>
    <nlmuniqueid>
     0370512
    </nlmuniqueid>
    <issnlinking>
     0002-953X
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anticonvulsants
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antimanic Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antipsychotic Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Triazines
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      298-46-4
     </registrynumber>
     <nameofsubstance>
      Carbamazepine
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      554-13-2
     </registrynumber>
     <nameofsubstance>
      Lithium Carbonate
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      84057-84-1
     </registrynumber>
     <nameofsubstance>
      lamotrigine
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      99-66-1
     </registrynumber>
     <nameofsubstance>
      Valproic Acid
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anticonvulsants
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antimanic Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antipsychotic Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bipolar Disorder
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Carbamazepine
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Embryonic and Fetal Development
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Fetal Diseases
     </descriptorname>
     <qualifiername majortopicyn="N">
      chemically induced
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Lithium Carbonate
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Postpartum Period
     </descriptorname>
     <qualifiername majortopicyn="Y">
      psychology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pregnancy
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prenatal Exposure Delayed Effects
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Triazines
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Valproic Acid
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <numberofreferences>
    104
   </numberofreferences>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2004
     </year>
     <month>
      4
     </month>
     <day>
      2
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2004
     </year>
     <month>
      6
     </month>
     <day>
      25
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2004
     </year>
     <month>
      4
     </month>
     <day>
      2
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     15056503
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

